Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

ria Vaccine

  • GenVec signed an agreement worth approximately $3.5 million with the Naval Medical Research Center (NMRC) to support malaria vaccine development.  Under the terms of the agreement, GenVec is responsible for producing clinical supplies of its malaria vaccine, which utilizes its novel, proprietary technology.  The NMRC plans to use this clinical material to assess the safety and efficacy of this next-generation vectored vaccine  using the clinical challenge model developed by the NMRC and the Walter Reed Army Institute of Research (WRAIR) malaria vaccine programs, which now are unified as the U.S. Military Malaria Vaccine Program (USMMVP).  GenVec retains the right to commercialize this novel technology.
     
  • GenVec received a grant of $600,000 over two years from the NIAID to support the Company's malaria vaccine program.  This grant will be used to identify novel antigens for malaria vaccine development.
     
  • Data were presented on GenVec's malaria vaccine program at the American Society of Tropical Medicine and Hygiene (ASTMH) 61st Annual Meeting, which took take place in Atlanta, Georgia on November 11-15, 2012.  Data presented at the conference highlighted GenVec's success in identifying novel antigens for use in its malarial vaccine development program.  Using a proprietary screening technology, GenVec identified new antigens that are as protective as the gold standard, circumsporozoite protein (CSP) in an industry-accepted mouse model of malaria.
    Recent data suggest that new antigens are needed and that CSP, used in vaccines being developed by others, may not be sufficient to generate a protective response in an adequate percentage of people. 
  • Core Technology

  • A research paper on GenVec's new vaccine vectors titled "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces
    '/>"/>

  • SOURCE GenVec, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
    2. GenVec Appoints Cynthia Collins as President and CEO
    3. GenVec Reports Inducement Award
    4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
    5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
    6. GenVec Reports Second Quarter 2012 Financial Results
    7. GenVec Reports Third Quarter 2012 Financial Results
    8. GenVec to Present at 25th Annual ROTH Conference
    9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... 2014 Investor-Edge has initiated coverage ... IMMU ), Aeterna Zentaris Inc. (NASDAQ: AEZS ... Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences ... can be accessed at: http://investor-edge.com/register . ... at 4,505.85, down 0.14%, the Dow Jones Industrial Average ...
    (Date:9/30/2014)... , Sept. 30, 2014 It is evident from ... market is not performing upto expectations due to the lack ... asscoaited with the intake of omega-3 fatty acids. Among omega-3 ... the fish oil, attributed to the large vegetarian population in ... omega-3 polyunsaturated fatty acid (PUFAs) ingredients is in growth stage ...
    (Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
    Breaking Medicine Technology:Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5
    ... 2007 - Corgenix Medical,Corporation (OTC BB: CONX) ... data demonstrating a significant correlation,between serum levels ... disease. The data was presented at,the XXIst ... and,Hemostasis (ISTH) in Geneva, Switzerland., Data released ...
    ... of rHuPH20 with Humira Estimated to ... from 64% to 100%,-, SAN DIEGO, ... Inc. , a biopharmaceutical company developing ... that,final results of the Enhanze(TM) Technology ...
    Cached Medicine Technology:Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
    (Date:9/30/2014)... Sheridan Healthcare, Inc. , ... today announced that Adam Blomberg, MD, the national ... present at the Society for Healthcare Strategy & ... . The conference will be held October 12-15 ... a four-day conference that draws in more than ...
    (Date:9/30/2014)... TN (PRWEB) September 30, 2014 ... of people throughout the United States and worldwide. ... Parkinson’s Disease are diagnosed each year, adding to ... with the disease. Approximately 400,000 people in the ... million worldwide. Add to these statistics the 2.4 ...
    (Date:9/30/2014)... 2014 (HealthDay News) -- In books and movies, plots involving ... Now, new research suggests that the stereotype may be ... at data on more than 12,000 people from Finland. ... Turku, Finland, found that women typically preferred men who were ... throughout their lives. On the other hand, men tended ...
    (Date:9/30/2014)... Bank, New Jersey (PRWEB) September 30, 2014 ... largest not-for-profit visiting nurse association—is pleased to announce that ... was honored with a NJBIZ “40 Under 40” ... of New Jersey’s most accomplished young businessmen and women ... who share a commitment to business growth, professional excellence ...
    (Date:9/30/2014)... FL (PRWEB) September 30, 2014 ... company focused on the peripheral nerve repair market, announced ... during the American Society for Surgery of the ... week in Boston. , The ASSH ... the Utilization of Processed Nerve Allografts for Large Gap ...
    Breaking Medicine News(10 mins):Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 2Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5
    ... estimated 2 million women in the United States are ... the chronic and abnormal swelling of the arm, chest, ... treatment. While physicians will recommend proven techniques to manage ... that patients often won,t follow the recommendations, or they ...
    ... times more apt to develop the lung artery disorder, study ... four times more likely to develop a debilitating and potentially ... shows. , Pulmonary hypertension is caused by high blood pressure ... who suffer from the condition can become tired, dizzy and ...
    ... the question, do barriers to health care for ... tuberculosis? The study, published in the November 15, ... and now available online, suggests that undocumented immigrants ... than documented immigrants or U.S.-born patients, resulting in ...
    ... CEO John G. Schulte with Chairman ... Emile J. Geisenheimer., ... lawsuit on behalf of those who purchased Spectranetics Company,stock (Nasdaq: ... officer violated U.S. securities laws through illegal,marketing practices and false statements ...
    ... of their Regional PPO Network Area Pay ... ... Life Insurance Company,of America (Guardian), a leading provider of employee and ... Extended Access "travel network" for its health plan members.,Members utilizing health ...
    ... Pittsburgh-based Foundation,Radiology Group (FRG) signed a multi-year ... exclusive provider of diagnostic,imaging services effective December 31, ... in Coudersport Pennsylvania,and services multiple counties in north ... provides a wide range of primary and,secondary health ...
    Cached Medicine News:Health News:MU study identifies patient strategies for managing symptoms of lymphedema 2Health News:MU study identifies patient strategies for managing symptoms of lymphedema 3Health News:Women at Higher Risk for Pulmonary Hypertension 2Health News:Health-care barriers for undocumented immigrants: Raising tuberculosis risk? 2Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 2Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 3Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 4Health News:Guardian Provides National Access to In-Network Medical Benefits 2Health News:Foundation Radiology Group Announces Multi-Year Deal with Charles Cole Memorial Hospital 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: